Osborne Clarke has advised iOnctura B.V., a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, on its EUR80 million Series B financing. The funding round was led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council (EIC), as well as existing investors M Ventures, Inkef Capital, VI Partners, Schroders Capital and 3B Future Health Fund. 

Osborne Clarke also had the pleasure to assist iOnctura on its Series A financing round.

The Osborne Clarke core deal team consisted of Partner Herke van Hulst, Senior Associate Wouter Kok and Associate Angela Saldanha and further included partner/ civil-law notary Cars-Jan van Gool, Associate Femke Izendoorn and Tax partner Job van der Pol.

Corporate communications and press contacts

If you are a journalist and would like comment or background from our legal experts, we can help. Our team will put you in touch with the best person. View a full list of our international press contacts by jurisdiction here.

Connect with one of our experts